Summary
Global Markets Direct’s, ‘Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2016’, provides an overview of the Vertex Pharmaceuticals Incorporated’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Vertex Pharmaceuticals Incorporated, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Vertex Pharmaceuticals Incorporated
- The report provides overview of Vertex Pharmaceuticals Incorporated including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Vertex Pharmaceuticals Incorporated’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Vertex Pharmaceuticals Incorporated’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Vertex Pharmaceuticals Incorporated’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vertex Pharmaceuticals Incorporated
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vertex Pharmaceuticals Incorporated’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Vertex Pharmaceuticals Incorporated Snapshot 6
Vertex Pharmaceuticals Incorporated Overview 6
Key Information 6
Key Facts 6
Vertex Pharmaceuticals Incorporated - Research and Development Overview 7
Key Therapeutic Areas 7
Vertex Pharmaceuticals Incorporated - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Vertex Pharmaceuticals Incorporated - Pipeline Products Glance 15
Vertex Pharmaceuticals Incorporated - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Vertex Pharmaceuticals Incorporated - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Vertex Pharmaceuticals Incorporated - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Vertex Pharmaceuticals Incorporated - Unknown Stage Pipeline Products 20
Unknown Products/Combination Treatment Modalities 20
Vertex Pharmaceuticals Incorporated - Drug Profiles 21
(ivacaftor + tezacaftor) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
telaprevir 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
VX-150 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
VX-371 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
VX-210 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
VX-970 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
VX-152 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
VX-440 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
VX-803 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
VX-984 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Inhibit HSP90 alpha/beta for Huntington's Disease 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
VE-465 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
VE-821 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
VX-241 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VXC-486 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Antagonize CGRP Receptor for Migraine 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Inhibit PI3K Gamma for Undisclosed Indication 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules for Multiple Sclerosis 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
VT-12008911 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
P-1055 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Vertex Pharmaceuticals Incorporated - Pipeline Analysis 46
Vertex Pharmaceuticals Incorporated - Pipeline Products by Target 46
Vertex Pharmaceuticals Incorporated - Pipeline Products by Route of Administration 48
Vertex Pharmaceuticals Incorporated - Pipeline Products by Molecule Type 49
Vertex Pharmaceuticals Incorporated - Pipeline Products by Mechanism of Action 50
Vertex Pharmaceuticals Incorporated - Recent Pipeline Updates 52
Vertex Pharmaceuticals Incorporated - Dormant Projects 59
Vertex Pharmaceuticals Incorporated - Discontinued Pipeline Products 60
Discontinued Pipeline Product Profiles 60
ALS-2158 60
telaprevir 60
VX-759 60
VX-983 60
Vertex Pharmaceuticals Incorporated - Company Statement 61
Vertex Pharmaceuticals Incorporated - Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67
List of Tables
Vertex Pharmaceuticals Incorporated, Key Information 6
Vertex Pharmaceuticals Incorporated, Key Facts 6
Vertex Pharmaceuticals Incorporated - Pipeline by Indication, 2016 8
Vertex Pharmaceuticals Incorporated - Pipeline by Stage of Development, 2016 10
Vertex Pharmaceuticals Incorporated - Monotherapy Products in Pipeline, 2016 11
Vertex Pharmaceuticals Incorporated - Combination Treatment Modalities in Pipeline, 2016 12
Vertex Pharmaceuticals Incorporated - Out-Licensed Products in Pipeline, 2016 13
Vertex Pharmaceuticals Incorporated - Out-Licensed Products/ Combination Treatment Modalities, 2016 14
Vertex Pharmaceuticals Incorporated - Phase III, 2016 15
Vertex Pharmaceuticals Incorporated - Phase II, 2016 16
Vertex Pharmaceuticals Incorporated - Phase I, 2016 17
Vertex Pharmaceuticals Incorporated - Preclinical, 2016 18
Vertex Pharmaceuticals Incorporated - Discovery, 2016 19
Vertex Pharmaceuticals Incorporated - Unknown, 2016 20
Vertex Pharmaceuticals Incorporated - Pipeline by Target, 2016 46
Vertex Pharmaceuticals Incorporated - Pipeline by Route of Administration, 2016 48
Vertex Pharmaceuticals Incorporated - Pipeline by Molecule Type, 2016 49
Vertex Pharmaceuticals Incorporated - Pipeline Products by Mechanism of Action, 2016 50
Vertex Pharmaceuticals Incorporated - Recent Pipeline Updates, 2016 52
Vertex Pharmaceuticals Incorporated - Dormant Developmental Projects,2016 59
Vertex Pharmaceuticals Incorporated - Discontinued Pipeline Products, 2016 60
Vertex Pharmaceuticals Incorporated, Other Locations 64
Vertex Pharmaceuticals Incorporated, Subsidiaries 64
List of Figures
Vertex Pharmaceuticals Incorporated - Pipeline by Top 10 Indication, 2016 8
Vertex Pharmaceuticals Incorporated - Pipeline by Stage of Development, 2016 10
Vertex Pharmaceuticals Incorporated - Monotherapy Products in Pipeline, 2016 11
Vertex Pharmaceuticals Incorporated - Out-Licensed Products in Pipeline, 2016 13
Vertex Pharmaceuticals Incorporated - Pipeline by Top 10 Target, 2016 46
Vertex Pharmaceuticals Incorporated - Pipeline by Top 10 Route of Administration, 2016 48
Vertex Pharmaceuticals Incorporated - Pipeline by Molecule Type, 2016 49
Vertex Pharmaceuticals Incorporated - Pipeline Products by Top 10 Mechanism of Action, 2016 50
